Mechanisms of Weight Loss With SGLT2 Inhibition
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 8/5/2018 |
| Start Date: | February 2015 |
| End Date: | August 2018 |
The purpose of this study is to investigate the effect of canagliflozin, a medication
approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in
people with type 2 diabetes who are overweight or obese.
Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than
absorb, glucose. Canagliflozin is also often associated with weight loss.
The study population will generally be type 2 diabetics, ages 18-75 years old, who are
overweight or obese.
approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in
people with type 2 diabetes who are overweight or obese.
Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than
absorb, glucose. Canagliflozin is also often associated with weight loss.
The study population will generally be type 2 diabetics, ages 18-75 years old, who are
overweight or obese.
Inclusion Criteria:
1. Type 2 diabetes
2. BMI 25-45 kg/m2
3. Hemoglobin A1C > 6.5% but < 9%
4. Normal renal function (GFR > 60)
5. Age 18-75
Exclusion Criteria:
1. Type 1 diabetes
2. History of recurrent UTI or mycotic genital infections
3. Treatment with insulin or a GLP1 agent
4. Pregnant or breastfeeding
We found this trial at
1
site
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Phone: 617-667-1996
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
